CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that data derived from its JTX-2011 program will be presented in two poster sessions at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, being held November 9-11, 2018 in Washington, D.C.
Poster Title: Emergence of an ICOS hi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011
Author: Christopher Harvey Ph.D., Jounce Therapeutics, Inc.
Session: Biomarkers and Immune Monitoring
Poster Session Number: 52
Location: Hall E
Date and Time: Saturday, November 10, 2018; 12:20pm–1:50pm ET and 7:00pm–8:30pm ET
Poster Title: Inducible T cell Co-stimulator (ICOS) is upregulated on lymphocytes following radiation of tumors and ICOS agonism in combination with radiation results in enhanced tumor control
Author: Michael J. Gough Ph.D., Earle A. Chile’s Research Institute, Providence Portland Medical Center, Portland Oregon
Session: Immune Effects of Chemotherapy, Radiation and Targeted Therapies
Poster Session Number: 455
Location: Hall E
Date and Time: Friday, November 9, 2018; 12:45pm–2:15pm ET and 6:30pm–8pm ET
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells. Preclinical data support that JTX-2011 may have a dual mechanism of action that stimulates anti-tumor T effector cells, and also reduces the immunosuppressive T regulatory cells in the tumor microenvironment. The company is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently conducting the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Jounce Therapeutics, Inc.
The Yates Network